Nussbaum Rodney L 4

What Happened

• Rodney L. Nussbaum, a director of Gyre Therapeutics, was granted a derivative award on June 10, 2026 giving him the right to purchase 40,000 shares of Gyre common stock. The Form 4 reports a $0.00 cash amount for the grant (reported as a derivative award), and the award will vest in 12 equal monthly installments through June 10, 2027, subject to continued service.

Key Details

• Transaction date: June 10, 2026 (Form filed June 30, 2026; Accession 0001140361-26-027003).
• Transaction type/code: A — Grant/Award of a derivative right to purchase shares.
• Quantity: 40,000 shares (right to purchase). Reported cash amount: $0.00.
• Vesting: 12 equal monthly installments through June 10, 2027, contingent on continued service (per footnote).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Timing: The Form 4 was filed 20 days after the transaction date; under SEC rules Form 4s are generally due within two business days, so this filing appears late.

Context

• This was an equity compensation award (a derivative right to purchase shares that vests over time), not an immediate open-market purchase or sale. Such grants are common for directors as compensation and are conditioned on continued service; they do not necessarily reflect immediate buying or selling intent.